[Antifungal drugs for pediatric use]

Area of Science:

• Mycology
• Pediatric Pharmacology
• Dermatology

Background:

• No specialized pediatric antifungal formulations exist in Japan.
• Pediatric use necessitates dose modifications and side effect precautions.
• Topical and systemic antifungal drug side effects require review.

Purpose of the Study:

• To review side effects of antifungal drugs in pediatric patients.
• To highlight the need for specialized pediatric formulations and dosing strategies.
• To assess the tolerability of new systemic antifungal agents in neonates and infants.

Main Methods:

• Literature review of topical and systemic antifungal drug side effects.
• Analysis of existing data on pediatric antifungal use in Japan.
• Evaluation of clinical reports on fluconazole, itraconazole, and terbinafine in neonates and infants.

Main Results:

• Newly introduced systemic antifungal drugs (fluconazole, itraconazole, terbinafine) were well tolerated.
• No specialized pediatric antifungal formulations are currently available in Japan.
• Dose adjustments and careful monitoring for side effects are crucial for pediatric patients.

Conclusions:

• Systemic antifungal agents like fluconazole, itraconazole, and terbinafine demonstrate good tolerability in pediatric populations.
• Development of specialized pediatric antifungal formulations and clear dosing guidelines is essential for safe and effective treatment in Japan.
• Ongoing monitoring for adverse events remains critical for optimizing antifungal therapy in children.